Citations

Clear

390 citation(s) found for "Loftus, E".

The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis
Bruining, David H. , Park, Sang Hyoung , Al‐Bawardy, Badr , Kane, Sunanda V. , Prabhu, Nayantara Coelho, Raffals, Laura E. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Al-Bawardy, Badr , Coelho Prabhu, Nayantara, Kisiel, John B. , Loftus, Edward V

Mayo Clinic

Journal of Clinical Medicine | August 5, 2019 | Volume: 8 | Issue: 8 | Pages: 1171

10.3390/jcm8081171 | PMID 31387259 Get It

Background and aims: Patient-reported outcomes (PROs) will become increasingly important as primary endpoints in future clinical trials. We aimed to evaluate the relationship between health-related quality of life (HRQoL) and the combination of patient-reported clinical symptoms (ClinPRO2) and Mayo endoscopic subscore (MES) in patients with ulcerative colitis (UC). Methods: We conducted a prospective cross-sectional study of 90 consecutive UC patients who were scheduled for sigmoidoscopy or colonoscopy. All patients completed the following questionnaires: (1) self-rated rectal bleeding and stool frequency (ClinPRO2); (2) Short Inflammatory Bowel Disease Questionnaire (SIBDQ); (3) European Quality of Life 5-Dimensions 3-Level (EQ5D3L); (4) Work Productivity and Activity Impairment questionnaire (WPAI); (5) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F); and (6) Hospital Anxiety and Depression Scale (HADS). The endoscopic images were graded according to the MES. “No symptoms” was defined as a symptom score of 0, and “mucosal healing” was defined as MES score of 0–1. Correlations between the combined ClinPRO2 and MES with HRQoL were assessed using Spearman’s correlation coefficients. Results: The combination of the ClinPRO2 and MES was well correlated to SIBDQ (r = −0.70), EQ5D3L (r = −0.51), WPAI (r = 0.62), FACIT-F (r = −0.58), and HADS-depression (r = 0.45). SIBDQ scores had strong correlations with FACIT-F (r = 0.86), WPAI (r = −0.80), and HADS-depression (r = −0.75) (p < 0.05 for all correlations). Patients with no symptoms reported the greatest all HRQoL scores. Conclusions: In patients with ulcerative colitis, the combination of a ClinPRO2 and the MES had good correlation with the SIBDQ. In addition, SIBDQ was well correlated to the various HRQoL.
P098 Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients
Alsughayer, Ahmad, Nicholas, M Hernandez, Edward, Loftus, Laura, Raffals, Faubion, William, Amy, Lightner

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S26-S26

10.14309/01.ajg.0000578464.92346.ab Get It

BACKGROUND: Limited knowledge exists as to what impact preoperative biologic therapy has on post-operative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation. METHODS: A retrospective chart review was performed on pediatric (<18 years of age) CD patients who underwent an abdominal operation between 1/1/2008 and 12/31/2017. Patients were grouped according to whether they received an anti-TNF (infliximab, adalimumab, certolizumab pegol) or no biologic therapy within 12 weeks prior to the operation. The primary outcome was a the overall 30-day postoperative infectious complication rate. Secondary outcomes included 30-day readmission rate and return to the operating room (ROR). RESULTS: A total of 69 pediatric CD patients met inclusion criteria (n = 54 anti-TNF therapy, n = 15 received no biologic therapy). There were no differences between the anti-TNF and no biologic cohorts with respect to demographics or CD characteristics. No significant differences in overall 30-day postoperative infectious complications existed between patients exposed to anti-TNF agents and those with no preoperative exposure, or in its subcategories of surgical infectious complications and non-surgical infectious complications. There was also no difference in the rate of ileus, readmission, or ROR. CONCLUSION(S): Preoperative exposure to anti-TNF biologic therapy does not add to overall or infectious 30-day postoperative morbidity in pediatric CD patients.
P035 Clostridium difficile infection in ulcerative colitis: Data from the tofacitinib clinical program and an insurance claims database
Edward, Loftus, Baumgart, Daniel, Marco, DiBonaventura, Jeffrey, Curtis, Gary, Chan, Eric, Maller, Quirk, Daniel, Fan, Haiyun, Koram, Nana , Salese, Leonardo , Su, Chinyu , Armuzzi, Alessandro , Marco, DiBonaventura, Gary, Chan

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S10-S10

10.14309/01.ajg.0000578212.86577.86 Get It

BACKGROUND: Patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), have a higher risk of Clostridium difficile infection (CDI) than the general population (1). The incidence of CDI is increasing among patients with IBD, and certain UC treatments may be associated with greater risk (1). We report CDI events in the tofacitinib UC clinical program, and the incidence of CDI among patients receiving other treatments for UC. METHODS: For the tofacitinib UC program, rates of CDI (patients with an adverse event [AE] of CDI, Clostridium difficile colitis, or Clostridium test-positive, plus concomitant oral metronidazole or vancomycin, counted once per cohort) are reported for Induction Cohort (patients from an 8-week Phase [P]2 and two 8-week P3 induction studies; placebo or tofacitinib 10 mg twice daily [BID; NCT00787202; NCT01465763; NCT01458951]); Maintenance Cohort (patients from a 52-week maintenance study; placebo or tofacitinib 5 or 10 mg BID [NCT01458574]); and Overall Cohort (all tofacitinib-treated patients in P2/3 induction and maintenance studies and an ongoing, open-label, long-term extension study [as of December 2016; NCT01470612]). Positive Clostridium difficile test at screening was an exclusion criterion for program entry. Overall Cohort incidence rate (IR) was calculated as number of unique patients with events per 100 patient-years (PY). For contextualization, CDI rates among patients receiving other UC medications were obtained from a retrospective cohort study utilizing data from the Truven MarketScan ® Database, an administrative healthcare claims database in the US. Patients with moderately to severely active UC, with either an inpatient or outpatient diagnosis code of CDI, plus a prescription for oral therapy (including metronidazole, vancomycin, and fidaxomicin) within 14 days of CDI diagnosis (observation period: October 1, 2010–September 30, 2015), were included. Truven cohort IRs were calculated as number of patients with events per 100 PY. RESULTS: In the tofacitinib Induction Cohort, CDI occurred in 3 patients (placebo, 1/282 [0.4%]; tofacitinib 10 mg BID, 2/938 [0.2%]). In the Maintenance Cohort, CDI occurred in 3 patients (placebo, 3/198 [1.5%]; tofacitinib 5 or 10 mg BID, 0/394 [0.0%]). In the Overall Cohort of all tofacitinib-treated patients (1,664 PY of follow-up), CDI occurred in 8/1,157 patients (0.7%), with an IR (95% confidence interval [CI]) of 0.48 (0.21, 0.95). Two cases were reported as serious AEs. All were mild (n = 4) or moderate (n = 4) in severity; 6 continued with study treatment, one temporarily discontinued, one permanently discontinued. All CDI cases resolved with treatment. In the Truven Cohort, 160 CDI events occurred during 4,918 PY of follow-up, with an overall CDI IR (95% CI) of 3.25 (2.77, 3.80); of which 116 were CDI-associated hospitalizations (4,936 PY of follow-up). Among patients receiving azathioprine, 6-mercaptopurine, or tumor necrosis factor inhibitors, CDI IRs were 3.23 (2.18, 4.62), 2.31 (1.26, 3.87), and 3.58 (2.95, 4.29), respectively. CONCLUSION(S): In the tofacitinib UC program, CDI rates among patients receiving tofacitinib were similar to or lower than those observed with placebo. The IR among patients receiving tofacitinib was numerically lower than those observed for immunomodulators and tumor necrosis factor inhibitors in the Truven Cohort.
P034 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical program
Gary, Lichtenstein, Bressler, Brian , Gary, Chan, Su, Chinyu , Gary, Friedman, Lawendy, Nervin, Ronald, Pedersen, Salese, Leonardo , Edward, Loftus, Gary, Chan

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S9-S9

10.14309/01.ajg.0000578208.09449.08 Get It

BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Safety and efficacy of tofacitinib were demonstrated in Phase (P) 2/3 induction studies (NCT00787202; NCT01465763; NCT01458951), a 52-week, P3 maintenance study (NCT01458574), and are being further investigated in an ongoing, open-label, long-term extension (OLE) study (NCT01470612). This analysis assessed age as a risk factor for adverse events (AEs) in the tofacitinib UC clinical program. METHODS: Analyses of AEs were performed for 2 cohorts: the Maintenance Cohort (patients who received placebo or tofacitinib 5 or 10 mg twice daily in the maintenance study) and the Overall Cohort (all tofacitinib-treated patients in the P2/P3/OLE studies [as of December 2016]), stratified by age (≥65 years vs <65 years). AEs of special interest included serious infections (SIs), opportunistic infections (OIs), herpes zoster (HZ), malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC, major adverse cardiovascular events (MACE), and gastrointestinal perforations. Risk factors (based on baseline characteristics) for SIs, OIs, HZ, and NMSC in the Overall Cohort were evaluated using multivariate Cox proportional regression models. RESULTS: AEs occurred in 75.3% (placebo) and 75.9% (tofacitinib) of patients in the Maintenance Cohort, and 82.1% in the Overall Cohort (in which 83.9% received predominantly tofacitinib 10 mg twice daily). Most patients (Maintenance Cohort: 180/198 [90.9%] and 364/394 [92.4%] receiving placebo and tofacitinib, respectively; Overall Cohort: 1,080/1,157 [93.3%]) were aged <65 years. In both the placebo and tofacitinib groups of the Maintenance Cohort, rates of AEs, serious AEs, severe AEs, and discontinuations due to AEs were numerically higher in patients aged ≥65 years (placebo: 83.3%, 11.1%, 11.1%, and 22.2%; tofacitinib: 80.0%, 16.7%, 10.0%, and 16.7%) vs <65 years (placebo: 74.4%, 6.1%, 9.4%, and 18.3%; tofacitinib: 75.5%, 4.4%, 7.1%, and 8.8%). AEs of special interest were generally infrequent in both the placebo and tofacitinib groups of the Maintenance Cohort. In the Overall Cohort, AE, serious AE, and severe AE rates were numerically higher in patients aged ≥65 years (88.3%, 19.5%, and 15.6%) vs <65 years (81.7%, 14.3%, and 12.2%). OI, HZ, malignancies (excluding NMSC), NMSC, and MACE rates were numerically higher in patients aged ≥65 years (3.9%, 14.3%, 2.6%, 5.3%, and 2.6%) vs <65 years (1.7%, 5.0%, 0.6%, 0.7%, and 0.2%); SI and gastrointestinal perforation rates were similar between age groups (≥65 years: 2.6% and 0.0%; <65 years: 2.9% and 0.4%). In multivariate modeling in the Overall Cohort, increasing age (every 10 years) was associated with increased risk of OIs (hazard ratio [95% confidence interval] 1.54 [1.15, 2.08]) and HZ (1.58 [1.34, 1.87]), but not SIs or NMSC (univariate modeling: 1.0 [0.78, 1.27] and 2.31 [1.46, 3.66]). CONCLUSION(S): In the tofacitinib UC program, AE rates were higher among patients aged ≥65 years vs those aged <65 years, regardless of whether they received tofacitinib or placebo. In multivariate analyses, older age was associated with increased OI and HZ risk. Although this is consistent with the general population, due to the small number of patients aged ≥65 years (<10% of the total), these findings should be interpreted with caution.
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
Steinhart, A. Hillary , Bressler, Brian , Khanna, Reena , Afif, Waqqas , Bitton, Alain , Borgaonkar, Mark , Chauhan, Usha, Halloran, Brendan P. , Jones, Jennifer , Kennedy, Erin , Meddings, Jonathan B., Plamondon, Sophie , Rosenfeld, Greg , Seow, Cynthia H. , Williams, Chadwick, Bernstein, Çharles N. , Panaccione, Remo , Marshall, John K. , Targownik, Laura E. , Leontiadis, Grigorios I. , Loftus, Edward V. , Moayyedi, Paul , Murthy, Sanjay K. , Schwartz, David A. , Bernstein, Charles Noah

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | July 10, 2019 | Volume: 2 | Issue: 3 | Pages: e1-e34

10.1093/jcag/gwz019 | PMID 31294378 Get It

Abstract Background & Aims Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
Koliani‐Pace, Jenna L., Singh, Siddharth , Luo, Michelle , Hirten, Robert , Kochhar, Gursimran , Chang, Shannon, Lukin, Dana J. , Gao, Youran, Bohm, Matthew , Shmidt, Eugenia , Meserve, Joseph , Winters, Adam C. , Chablaney, Shreya , Yang, Jiao, Huang, Zhongwen, Boland, Brigid S. , Shashi, Preeti , Weiss, Aaron , Varma, Sashidhar, Fischer, Monika , Sultan, Keith , Shen, Bo , Kane, Sunanda V. , Loftus, Edward V. , Sandborn, William J. , Lasch, Karen, Dulai, Parambir S. , Aniwan, Satimai , Loftus, Edward V , Chang, Shannon, Swaminath, Arun C. , Gupta, Nitin Kumar , Faleck, David M. , Weiss, Aaron, Hudesman, David , Sands, Bruce E , Colombel, Jean‐Frédéric , Siegel, Corey A

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 25 | Issue: 11 | Pages: 1854-1861

10.1093/ibd/izz071 | PMID 31050734 Get It

Abstract Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns and outcomes of vedolizumab in 2 time frames after FDA approval. Methods We used 2 data sets for time trend analysis, an academic multicenter vedolizumab consortium (VICTORY) and the Truven MarketScan database, and 2 time periods, May 2014–June 2015 (Era 1) and July 2015–June 2017 (Era 2). VICTORY cumulative 12-month clinical remission, corticosteroid-free remission, and mucosal healing rates, and Truven 12-month hospitalization and surgery rates, were compared between Eras 1 and 2 using time-to-event analyses. Results A total of 3661 vedolizumab-treated patients were included (n = 1087 VICTORY, n = 2574 Truven). In both cohorts, CD and UC patients treated during Era 2 were more likely to be biologic naïve. Compared with Era 1, Era 2 CD patients in the VICTORY consortium had higher rates of clinical remission (31% vs 40%, P = 0.03) and mucosal healing (42% vs 58%, P < 0.01). These trends were not observed for UC. In the Truven database, UC patients treated during Era 2 had lower rates of inflammatory bowel disease–related hospitalization (22.4% vs 9.6%, P < 0.001) and surgery (17.2% vs 9.4%, P = 0.008), which was not observed for CD. Conclusion Since FDA approval, remission and mucosal healing rates have increased for vedolizumab-treated CD patients, and vedolizumab-treated UC patients have had fewer hospitalizations and surgeries. This is likely due to differences between patient populations treated immediately after drug approval and those treated later.
De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel
Sparrow, Miles , Melmed, Gil , Devlin, Shane , Raffals, Laura E. , Loftus, Edward V. , Rubin, David T. , Bressler, Brian , Cheifetz, Adam S. , Jones, Jennifer , Velayos, Fernando, Loftus, Edward V , Melmed, Gil Y , Rubin, David T , Kozuch, Patricia L. , Spiegel, Brennan , Baidoo, Leonard , Irving, Peter Miles , Kaplan, Gilaad G. , Siegel, Corey A

Mayo Clinic

GastroHep | April 30, 2019 | Volume: 1 | Issue: 3 | Pages: 108-117

10.1002/ygh2.337 Get It

Response to Chapman and Jones
Lichtenstein, Gary R. , Loftus, Edward V. , Isaacs, Kim L. , Loftus, Edward V , Regueiro, Miguel , Sands, Bruce E

Mayo Clinic

American Journal of Gastroenterology | April 13, 2019 | Volume: 114 | Issue: 5 | Pages: 828-828

10.14309/ajg.0000000000000217 | PMID 30985301 Get It

Response to Ribaldone
Lichtenstein, Gary R. , Loftus, Edward V. , Isaacs, Kim L. , Loftus, Edward V , Regueiro, Miguel , Sands, Bruce E

Mayo Clinic

American Journal of Gastroenterology | April 13, 2019 | Volume: 114 | Issue: 5 | Pages: 826-827

10.14309/ajg.0000000000000216 | PMID 30985300 Get It

Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease
Loftus, Edward V. , McKenna, Nicholas P. , Raffals, Laura E. , Loftus, Edward V , McKenna, Nicholas P , Lightner, Amy L.

Mayo Clinic

Current Drug Targets | March 27, 2019 | Volume: 20 | Issue: 13 | Pages: 1317-1322

10.2174/1389450120666190325130142 | PMID 30914021 Get It

Background: : The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. Objective: : To determine the risk of vedolizumab on postoperative complications. Method:: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn’s disease or ulcerative colitis individually, and those which included pediatric patients alone. Results:: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn’s disease literature. Conclusion:: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn’s disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.